NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
NVONovo Nordisk(NVO) ZACKS·2024-10-22 00:55

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors. Novo Nordisk's Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin productio ...